Clearside reports positive ODYSSEY Phase 2b results for CLS-AX in wet AMD; all endpoints met

Clearside Biomedical, Inc.

ODYSSEY Phase 2b trial of suprachoroidal CLS-AX achieved primary and secondary outcomes; stable BCVA and CSRT through 36 weeks.
67% of CLS-AX participants required no additional treatment up to 6 months; 90% up to 4 months, 81% up to 5 months.
Treatment burden reduced by ~84% compared to average monthly injections prior to screening.
No ocular or treatment-related SAEs; no endophthalmitis, no retinal vasculitis; well-tolerated safety profile.
Company plans to advance CLS-AX into Phase 3 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.